How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

21,580 results for

Serotonin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Esketamine (Spravato) - In combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin–norepinephrine reuptake inhibitor (SNRI), for adults with treatment-resistant major depressive disorder, who have not responded to at least two differ

Esketamine (Spravato) - In combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin–norepinephrine reuptake inhibitor (SNRI), for adults with treatment-resistant major depressive disorder, who have not responded to at least two differ 1 Published 7 September 2020 SMC2258 esketamine 28mg nasal spray, solution (Spravato®) Janssen-Cilag Ltd 7 August 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area (...) Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission esketamine (Spravato®) is accepted for use within NHSScotland. Indication under review: In combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI), for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants

2020 Scottish Medicines Consortium

2. Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs

Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Search Guidance and support Take action (...) now for new rules in 2021 Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs Cases of serotonin syndrome have been identified in associated with bupropion, especially in overdose or when bupropion is administered with other drugs with a serotonergic effect. Published 16 November 2020 Last updated 16 November 2020 — From: Contents Advice for healthcare professionals: cases of serotonin syndrome have been reported in association with bupropion and coadministration

2020 MHRA Drug Safety Update

3. Serotonin syndrome

Serotonin syndrome Serotonin syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Serotonin syndrome Last reviewed: February 2019 Last updated: January 2018 Summary Clinical manifestation of excess serotonin in the central nervous system, resulting from the therapeutic use or overdose of serotonergic drugs. Characterised by a triad of clinical features: neuromuscular excitation, autonomic effects, and altered (...) mental status. Better described as a spectrum of toxicity, ranging from mild to severe, rather than a 'syndrome'. Diagnosis is clinical and should be based on the Hunter Serotonin Toxicity Criteria (HSTC), of which clonus is a key diagnostic feature. Treatment is guided by the severity of toxicity and involves cessation of the drug(s), supportive care, and anti-serotonergic drugs in select patients. Definition An excess of synaptic serotonin in the central nervous system that clinically manifests

2018 BMJ Best Practice

4. Selective Serotonin Reuptake Inhibitor Use May Increase the Risk of Dental Implant Failure

Selective Serotonin Reuptake Inhibitor Use May Increase the Risk of Dental Implant Failure UTCAT3400, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Selective Serotonin Reuptake Inhibitor Use May Increase the Risk of Dental Implant Failure Clinical Question Does history of selective serotonin reuptake inhibitor (SSRI) use affect implant success as compared to patients with no history of SSRI use? Clinical Bottom Line (...) For a patient with a history of selective serotonin reuptake inhibitor use, evidence shows an association for an increased risk of dental implant failure. However, evidence from a prospective cohort study would be needed to show a true “cause-effect” relationship. Clinicians and patients should be aware that use of certain medications may affect bone homeostasis and osseointegration of dental implants. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient

2019 UTHSCSA Dental School CAT Library

5. Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines

Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines - GOV.UK GOV.UK uses cookies to make the site simpler. Search Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines Tapentadol may increase seizure risk in patients taking other medicines that lower seizure (...) threshold, for example, antidepressants and antipsychotics. Serotonin syndrome has also been reported when tapentadol is used in combination with serotoninergic antidepressants. Published 9 January 2019 Last updated 9 January 2019 — From: Therapeutic area: , , , Contents Advice for healthcare professionals: as for all opioid medicines, tapentadol can induce seizures tapentadol should be prescribed with care in patients with a history of seizure disorders or epilepsy tapentadol may increase seizure risk

2019 MHRA Drug Safety Update

6. Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition. (Abstract)

Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition. Previous research has implicated the serotonin-2B (5-HT2B) receptor as a possible contributor to the antidepressant-like response. Aripiprazole has been successfully used in combination with selective serotonin reuptake inhibitors (SSRIs) in treatment-resistant depression and it, among all receptors, exhibits the highest affinity for the 5-HT2B

2020 Neuropsychopharmacology

7. A positron emission tomography occupancy study of brexpiprazole at dopamine D<sub>2</sub> and D<sub>3</sub> and serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors, and serotonin reuptake transporters in subjects with schizophrenia. (Abstract)

A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia. The objective of this study (NCT01854944) was to assess D2/D3, 5-HT1A, 5-HT2A and serotonin transporter (SERT) occupancies of brexpiprazole in adult subjects with schizophrenia in order to identify the in vivo pharmacologic profile that may be relevant

2020 Neuropsychopharmacology

8. Protective Effects of Serotonin and its Derivatives, N-Feruloylserotonin and N-(p-Coumaroyl) Serotonin, Against Cisplatin-Induced Renal Damage in Mice. (Abstract)

Protective Effects of Serotonin and its Derivatives, N-Feruloylserotonin and N-(p-Coumaroyl) Serotonin, Against Cisplatin-Induced Renal Damage in Mice. This study examined whether serotonin and two of its derivatives, N -feruloylserotonin and N -( p -coumaroyl) serotonin, have a renoprotective effect in a mouse model of cisplatin-induced acute renal failure. Cisplatin (20 mg/kg body weight) was administered by intraperitoneal injection to male BALB/c mice that had received oral serotonin, N (...) -feruloylserotonin or N -( p -coumaroyl) serotonin (7.5 mg/kg body weight per day) during the preceding 2 days. At 3 days after the cisplatin injection, serum and renal biochemical factors, oxidative stress, inflammation and apoptosis-related protein expression were evaluated, and histological examinations were performed. Cisplatin caused reduction in body weight and an increase in kidney weight; however, N -( p -coumaroyl) serotonin and N -feruloylserotonin attenuated these effects. Moreover, the serotonin

2019 American Journal of Chinese Medicine

9. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy. Full Text available with Trip Pro

Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy. To guide clinicians in selecting the "next line" selective serotonin reuptake inhibitor (SSRI) for adolescents with treatment-resistant major depressive disorder, we sought to compare response rates among SSRIs in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study and to jointly model

2019 Journal of Child and Adolescent Psychopharmacology

10. An atypical case of serotonin syndrome with normal dose of selective serotonin inhibitors: A case report. Full Text available with Trip Pro

An atypical case of serotonin syndrome with normal dose of selective serotonin inhibitors: A case report. As increasing frequency of serotonergic drug use, SS (serotonin syndrome) occurred more than ever. But clinicians have not enough knowledge and experience about SS as a potentially life-threatening condition. SS is usually caused by the increased serotonin activity in the central nervous system which may due to a serotonergic agent overdose or the concomitant use of 2 or more serotonergic (...) antidepressants. We report a case of SS due to a normal dose of selective serotonin inhibitors (SSRIs) thus to remind clinicians to pay attention to such patients and make an early diagnosis and initiation of therapy in the clinical practice.We report here a 49-year-old man presented with lethargic, less communicative, and insomnia for 20 days while a diagnosis of depression was considered and he was treated with SSRIs.The patient in our case fulfilled the 3 criteria existed now for diagnosing SS, including

2019 Medicine

11. Disrupted placental serotonin synthetic pathway and increased placental serotonin: Potential implications in the pathogenesis of human fetal growth restriction. Full Text available with Trip Pro

Disrupted placental serotonin synthetic pathway and increased placental serotonin: Potential implications in the pathogenesis of human fetal growth restriction. Placental insufficiency contributes to altered maternal-fetal amino acid transfer, and thereby to poor fetal growth. An important placental function is the uptake of tryptophan and its metabolism to serotonin (5-HT) and kynurenine metabolites, which are essential for fetal development. We hypothesised that placental 5-HT content

2019 Placenta

12. Acute Treatment of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors for Panic Disorder: A Systematic Review and Network Meta-Analysis

Acute Treatment of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors for Panic Disorder: A Systematic Review and Network Meta-Analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2021 PROSPERO

13. Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studies Full Text available with Trip Pro

Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studies Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studies | medRxiv Search for this keyword Suicide risk with selective serotonin reuptake inhibitors and new-generation (...) and/or intentional self-harm. Data sources We searched MEDLINE, PsycINFO, Web of Science, PsycARTICLES and SCOPUS for case-control and cohort studies published 1990-2020. Eligibility criteria for study selection Cohort and case-control studies in adults (aged ≥18 years) with depression and any unspecified condition reporting suicide risk for patients exposed to selective serotonin reuptake inhibitors (SSRI) or new-generation serotonergic-noradrenergic antidepressants (SNA) relative to unexposed patients. Data

2020 Cold Spring Harbor Laboratory

14. Perinatal selective serotonin reuptake inhibitor exposure and behavioral outcomes: a systematic review and meta-analyses of animal studies Full Text available with Trip Pro

Perinatal selective serotonin reuptake inhibitor exposure and behavioral outcomes: a systematic review and meta-analyses of animal studies Perinatal selective serotonin reuptake inhibitor exposure and behavioral outcomes: a systematic review and meta-analyses of animal studies | bioRxiv Search for this keyword New Results Perinatal selective serotonin reuptake inhibitor exposure and behavioral outcomes: a systematic review and meta-analyses of animal studies A.S. Ramsteijn , L. Van de Wijer , J (...) % of pregnant women use selective serotonin reuptake inhibitor (SSRI) antidepressants. There is no consensus on the potential long-term neurodevelopmental outcomes of early SSRI exposure. Our aim was to determine whether there is an overall effect of perinatal SSRI exposure in animals on a spectrum of behavioral domains. After a comprehensive database search in PubMed, PsycINFO, and Web of Science, we included 99 publications. We performed nine meta-analyses and two qualitative syntheses corresponding

2019 Cold Spring Harbor Laboratory

15. The 5-Hydroxytryptamine signaling map: an overview of serotonin-serotonin receptor mediated signaling network Full Text available with Trip Pro

The 5-Hydroxytryptamine signaling map: an overview of serotonin-serotonin receptor mediated signaling network The monoamine neurotransmitter, 5-Hydroxytryptamine or serotonin, is derived from tryptophan and synthesized both centrally and systemically. Fourteen structurally and functionally distinct receptor subtypes have been identified for serotonin, each of which mediates the neurotransmitter's effects through a range of downstream signaling molecules and effectors. Although it is most (...) frequently described for its role in the etiology of neuropsychiatric and mood disorders, serotonin has been implicated in a slew of fundamental physiological processes, including apoptosis, mitochondrial biogenesis, cell proliferation and migration. Its roles as the neurotransmitter have also emerged in pathogenic conditions ranging from anorexia nervosa to cancer. This has necessitated the understanding of the signaling mechanisms underlying the serotonergic system, which led us to construct

2018 Journal of cell communication and signaling

16. Comparative effectiveness of cognitive-behavioral treatment and Serotonin and serotonin noradrenaline reuptake inhibitors for anxiety in children and adolescents: A network meta analysis

Comparative effectiveness of cognitive-behavioral treatment and Serotonin and serotonin noradrenaline reuptake inhibitors for anxiety in children and adolescents: A network meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2020 PROSPERO

17. Selective Serotonin Reuptake Inhibitor (SSRI) and Serotonin-Norepinephrine Reuptake inhibitor (SNRI) associated Cutaneous Adverse Drug Reactions (CADRs): A systematic review of case reports and case series

Selective Serotonin Reuptake Inhibitor (SSRI) and Serotonin-Norepinephrine Reuptake inhibitor (SNRI) associated Cutaneous Adverse Drug Reactions (CADRs): A systematic review of case reports and case series Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2020 PROSPERO

18. Salivary serotonin does not correlate with central serotonin turnover in adult phenylketonuria (PKU) patients Full Text available with Trip Pro

Salivary serotonin does not correlate with central serotonin turnover in adult phenylketonuria (PKU) patients Phenylketonuria (PKU) is an inborn error of metabolism associated with an increased risk of behavioural and mood disorders. There are currently no reliable markers for monitoring mood in PKU. The purpose of this study was to evaluate salivary serotonin as a possible non-invasive marker of long-term mood symptoms and central serotonin activity in patients with PKU.20 patients were (...) recruited from our Adult Metabolic Diseases Clinic. Age, sex, plasma phenylalanine (Phe) level, DASS (Depression Anxiety Stress Scales) depression score, DASS anxiety score, BMI, salivary serotonin, salivary cortisol, 2-year average Phe, 2-year average tyrosine (Tyr), and 2-year average Phe:Tyr ratio were collected for each patient. Spearman's ρ correlation analysis was used to determine if there was any relationship between any of the parameters.There were positive correlations between DASS anxiety

2018 Molecular genetics and metabolism reports

19. Serotonin and serotonin transporter levels in autistic children Full Text available with Trip Pro

Serotonin and serotonin transporter levels in autistic children To assess the possible correlation between serotonin and serotonin transporter (SERT) with the autism severity and investigate the association between these parameters in autistic children to assess their possible role for diagnosis of autism severity.A comparative cross-sectional study was carried out in the Chemistry and Biochemistry Department, College of Medicine, Al-Nahrain University, Baghdad, Iraq while the samples were (...) taken from 60 male autistic children recruited to the Department of Pediatrics at Al-Sader Hospital, Baghdad, Iraq between November 2014 amd April 2015. Levels of serotonin and serotonin transporters (SERT) were determined in 60 male autistic Iraqi patients classified into mild, moderate and severe (20 for each). These levels were compared with those of 26 healthy control children. Results: Levels of serotonin and SERT were significantly increased in autistic children than that of gender and age

2018 Saudi medical journal

20. Cell proliferation and migration mechanism of caffeoylserotonin and serotonin via serotonin 2B receptor in human keratinocyte HaCaT cells Full Text available with Trip Pro

Cell proliferation and migration mechanism of caffeoylserotonin and serotonin via serotonin 2B receptor in human keratinocyte HaCaT cells Caffeoylserotonin (CaS), one derivative of serotonin (5-HT), is a secondary metabolite produced in pepper fruits with strong antioxidant activities. In this study, we investigated the effect of CaS on proliferation and migration of human keratinocyte HaCaT cells compared to that of 5-HT. CaS enhanced keratinocyte proliferation even under serum deficient (...) condition. This effect of CaS was mediated by serotonin 2B receptor (5-HT2BR) related to the cell proliferation effect of 5-HT. We also confirmed that both CaS and 5-HT induced G1 progression via 5-HT2BR/ERK pathway in HaCaT cells. However, Akt pathway was additionally involved in upregulated expression levels of cyclin D1 and cyclin E induced by CaS by activating 5-HT2BR. Moreover, CaS and 5-HT induced cell migration in HaCaT cells via 5-HT2BR. However, 5-HT regulated cell migration only through ERK/AP

2018 BMB reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>